On the last 27th – 28th of October, nearly 50 representatives of TransBioLine consortium met face-to-face in Barcelona for the first time after the pandemic to hold the 5th Consortium Meeting, a 2-day event organised by us.
Even with virtual attendance being offered, around 50 representatives of the TransBioLine consortium had the opportunity to meet again face-to-face to share updates and upcoming project activities. During this 5th TransBioLine Consortium Meeting, organised by us, the participants brainstormed on the project’s sustainability and agreed on the next steps to follow to secure the Project’s legacy. Additionally, other relevant topics like project progression were also approached during this F2F event.
Following two days of fruitful discussions, to close the meeting, the SAB (Scientific Advisory Board) and EAB (Ethical Advisory Board) members provided their feedback and suggestions to achieve the project objectives successfully.
About TransBioLine
TransBioLine promises a decisive advance in safety biomarker identification, development, and qualification for a more informed decision-making process during drug development, or even later, during the regulatory processes of drug approval, facilitating the evaluation of drug safety: all in all, to streamline drug development and ensure patient safety.
TransBioLine is a project supported by the Innovative Health Initiative, a public-private partnership between the European Union and EFPIA.
For more information visit TransBioLine project website.
• Senior communications/PR professional who has built and led regional corporate communications teams at major global companies in the healthcare, financial services, food & beverage, and packaging sectors.
• University degree in Advertising and Public Relationships, Universitat Autònoma de Barcelona.
• University degree in Industrial Engineering, Universidad Tecnológica Nacional.
• Master in Corporate Communication, Protocol and Events, Universitat Oberta de Catalunya.
• BSc in Biology by the University of Barcelona, complemented by a Master degree in “Basic fundamentals of oncogenesis” by the University of Paris VI and Master in Business and Administration by the ESG (Paris).
• Ph.D. Medical Informatics.
• University degree in Political and Administration Sciences, Universitat Pompeu Fabra.
• Bachelor’s Degree in Communication from Instituto Tecnológico y de Estudios Superiores de Monterrey and in Journalism from Universidad Nacional Autónoma de México.
• University degree in Political Science and International Relations, Universidad Nacional de Rosario.
• PhD in Psychology, University of Edinburgh.
• University degree in Nursing, Universitat Autònoma de Barcelona.
• University double degree in Law & Political Sciences, Universidad Autónoma de Madrid.
• University degree in Telecommunication Engineering, Universidad Politécnica de Madrid.
• University degree in Business Administration, University of Barcelona.
• Ph.D. in Molecular Toxicology, University of Colorado Boulder.
• B.A. in Economics with Honors and Distinction from Stanford University.
• University degree in Tourism, Universitat de Barcelona.
• Ph.D. in Psychology and Neuroscience, Universidad Complutense de Madrid.
• University degree in Psychology, Universitat Autònoma de Barcelona.
• University degree in Social Sciences, Universidad de Vigo.
• University degree in Economy and Business Administration (Extraordinary Award), Universitat Autònoma de Barcelona.